ARC Desk

Vaccines Market All Time on High Demand with Stunning CAGR 6.4% by 2026

Lehdistötiedote   •   Joulu 04, 2019 09:37 EET

The international ​Vaccines Market is expected to exceed $55.2 billion by 2026 and the market is anticipated to display a CAGR of 6.4percent from 2019 through 2026.

The report, titled Vaccines Market offers a comprehensive overview of the market. It covers various growth drivers and restraints impacting the global Vaccines Market between 2019 and 2026. The report also revels both historical and forecast figures of the market. The rate of growth that the market is likely to exhibit during the course of the forecast period is highlighted as well.

The report covers in-depth information on the Vaccines Market sourced from within the industry. In addition to the aforementioned factors, the report includes expert opinions. The report therefore contains every relevant insight needed for a company to strengthen their foothold in this market. Information is included in the report in a coherent chapter-wise manner. This is intended to improve the overall readability of the study. Furthermore, Acumen Research and Consulting promises customization to include the most relevant information for the readers.

Download Free Sample Copy of Vaccines Market Report@ https://www.acumenresearchandconsulting.com/request-sample/1599

Competitive landscape

Some of the key players in the global Vaccines Market include Astellas Pharma Inc.; Bavarian Nordic; CSL Limited; Daiichi Sankyo Company, Limited; Emergent BioSolutions, Inc.; GlaxoSmithKline plc; Johnson & Johnson; MedImmune, LLC; Merck & Co., Inc.; Mitsubishi Tanabe Pharma Corporation. Over the past few years, the companies have increased their production capacity to meet the growing demand. Companies are expected to focus on new product launches and on consolidating their presence in the coming years. Leading companies are therefore adopting various strategies to establish their stronghold. For instance, several companies are focusing on product launches, and forging collaborations to gain competitive edge. Key manufacturers are adopting merge & acquisition methods with the local players to increase their business footprints.

Furthermore, the report examines the bargaining power of buyers and suppliers using Porter’s five forces model of analysis. It also helps in evaluating the threat from new entrants and substitutes. Other analyses conducted while compiling the study are price trend analysis and top-down analysis. The latter is conducted to highlight the bigger picture to support investment idea and then help in selection of correct stocks.

Regional outlook

In terms of region, the report covers Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa. Growth witnessed by the market across each of these regions is studied in detail. Additionally, the report also analyse the impact of government regulations on the Vaccines Market in the aforementioned regions. While developed countries are expected to remain lucrative markets, leading players are likely to shift their focus towards emerging economies.

Factors such as rising awareness, investment in research and development, expansion of pharmaceutical and healthcare sector, and government support are the key aspects driving Vaccines Market in Asia Pacific and Latin America.

Market Segment Analysis:

Acumen Research report focuses on market attractiveness by assessing the key market segments. The report also combines region-wise segments for a better understanding of the supply and demand ratio of this market. This exclusive study of the report analyzes the present and future market scenario and the industry trends that are influencing the growth of the segments. Besides, the report also covers the value chain analysis, supply chain analysis, and year-on-year basis analysis of this market.

Market Segmentation:

Market By Technology

  • Conjugate Vaccines
  • Inactivated Vaccines
  • Live Attenuated Vaccines,
  • Toxoid Vaccines
  • Recombinant Vaccines

By Indication

  • Dengue
  • DTP
  • Hepatitis
  • HPV
  • Influenza
  • Meningococcal
  • MMR
  • Pneumococcal
  • Polio
  • Rotavirus
  • Varicella

By Type

  • Monovalent
  • Multivalent

By Route of Administration

  • Intramuscular
  • Subcutaneous
  • Oral
  • Others

By Type of Patient

  • Children
  • Adult

Market By Geography

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Vaccine
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Vaccine Market By Technology
1.2.2.1. Global Vaccine Market Revenue and Growth Rate Comparison By Technology (2015-2026)
1.2.2.2. Global Vaccine Market Revenue Share By Technology in 2017
1.2.2.3. Conjugate Vaccines
1.2.2.4. Inactivated Vaccines
1.2.2.5. Live Attenuated Vaccines
1.2.2.6. Toxoid Vaccines
1.2.2.7. Recombinant Vaccines
1.2.3. Vaccine Market By Indication
1.2.3.1. Global Vaccine Market Revenue and Growth Rate Comparison By Indication (2015-2026)
1.2.3.2. Global Vaccine Market Revenue Share By Indication in 2017
1.2.3.3. Dengue
1.2.3.4. DTP
1.2.3.5. Hepatitis
1.2.3.6. HPV
1.2.3.7. Influenza
1.2.3.8. Meningococcal
1.2.3.9. MMR
1.2.3.10. Pneumococcal
1.2.3.11. Polio
1.2.3.12. Rotavirus
1.2.3.13. Varicella
1.2.4. Vaccine Market By Type
1.2.4.1. Global Vaccine Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.4.2. Global Vaccine Market Revenue Share By Type in 2017
1.2.4.3. Monovalent
1.2.4.4. Multivalent
1.2.5. Vaccine Market By Route of Administration
1.2.5.1. Global Vaccine Market Revenue and Growth Rate Comparison By Route of Administration (2015-2026)
1.2.5.2. Global Vaccine Market Revenue Share By Route of Administration in 2017
1.2.5.3. Intramuscular
1.2.5.4. Subcutaneous
1.2.5.5. Oral
1.2.5.6. Others
1.2.6. Vaccine Market By Type of Patient
1.2.6.1. Global Vaccine Market Revenue and Growth Rate Comparison By Type of Patient (2015-2026)
1.2.6.2. Global Vaccine Market Revenue Share By Type of Patient in 2017
1.2.6.3. Children
1.2.6.4. Adult
1.2.7. Vaccine Market By Geography
1.2.7.1. Global Vaccine Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.7.2. North America Vaccine Market Revenue and Growth Rate (2015-2026)
1.2.7.3. Europe Vaccine Market Revenue and Growth Rate (2015-2026)
1.2.7.4. Asia-Pacific Vaccine Market Revenue and Growth Rate (2015-2026)
1.2.7.5. Latin America Vaccine Market Revenue and Growth Rate (2015-2026)
1.2.7.6. Middle East and Africa (MEA) Vaccine Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Vaccine Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Vaccine Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Vaccine Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Vaccine Major Manufacturers in 2017

CHAPTER 4. Vaccine Market By Technology
4.1. Global Vaccine Revenue By Technology
4.2. Conjugate Vaccines
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Inactivated Vaccines
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Live Attenuated Vaccines
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Toxoid Vaccines
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Recombinant Vaccines
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. Vaccine Market By Indication
5.1. Global Vaccine Revenue By Indication
5.2. Dengue
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. DTP
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Hepatitis
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. HPV
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.6. Influenza
5.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.7. Meningococcal
5.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.8. MMR
5.8.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.8.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.9. Pneumococcal
5.9.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.9.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.10. Polio
5.10.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.10.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.11. Rotavirus
5.11.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.11.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.12. Varicella
5.12.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.12.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. Vaccine Market By Type
6.1. Global Vaccine Revenue By Type
6.2. Monovalent
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Multivalent
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. Vaccine Market By Route of Administration
7.1. Global Vaccine Revenue By Route of Administration
7.2. Intramuscular
7.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.3. Subcutaneous
7.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.4. Oral
7.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.5. Others
7.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 8. Vaccine Market By Type of Patient
8.1. Global Vaccine Revenue By Type of Patient
8.2. Children
8.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
8.3. Adult
8.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 9. North America Vaccine Market By Country
9.1. North America Vaccine Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. North America Vaccine Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. U.S.
9.3.1. U.S. Vaccine Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
9.4. Canada
9.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 10. Europe Vaccine Market By Country
10.1. Europe Vaccine Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Europe Vaccine Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. UK
10.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.4. Germany
10.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.5. France
10.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.6. Spain
10.6.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.6.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.7. Rest of Europe
10.7.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.7.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 11. Asia-Pacific Vaccine Market By Country
11.1. Asia-Pacific Vaccine Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Asia-Pacific Vaccine Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. China
11.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
11.4. Japan
11.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
11.5. India
11.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
11.6. Australia
11.6.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.6.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
11.7. South Korea
11.7.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.7.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
11.8. Rest of Asia-Pacific
11.8.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.8.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 12. Latin America Vaccine Market By Country
12.1. Latin America Vaccine Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Latin America Vaccine Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. Brazil
12.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
12.4. Mexico
12.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
12.5. Rest of Latin America
12.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 13. MIDDLE EAST & AFRICA VACCINE MARKET BY COUNTRY
13.1. Middle East & Africa Vaccine Market Revenue and Growth Rate, 2015 - 2026 ($Million)
13.2. Middle East & Africa Vaccine Market Revenue Share Comparison, 2015 & 2026 (%)
13.3. GCC
13.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
13.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
13.4. South Africa
13.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
13.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
13.5. Rest of Middle East & Africa
13.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
13.5.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 14. COMPANY PROFILE
14.1. Astellas Pharma Inc.
14.1.1. Company Snapshot
14.1.2. Overview
14.1.3. Financial Overview
14.1.4. Product Portfolio
14.1.5. Key Developments
14.1.6. Strategies
14.2. Bavarian Nordic
14.2.1. Company Snapshot
14.2.2. Overview
14.2.3. Financial Overview
14.2.4. Product Portfolio
14.2.5. Key Developments
14.2.6. Strategies
14.3. CSL Limited
14.3.1. Company Snapshot
14.3.2. Overview
14.3.3. Financial Overview
14.3.4. Product Portfolio
14.3.5. Key Developments
14.3.6. Strategies
14.4. Daiichi Sankyo Company, Limited
14.4.1. Company Snapshot
14.4.2. Overview
14.4.3. Financial Overview
14.4.4. Product Portfolio
14.4.5. Key Developments
14.4.6. Strategies
14.5. Emergent BioSolutions, Inc.
14.5.1. Company Snapshot
14.5.2. Overview
14.5.3. Financial Overview
14.5.4. Product Portfolio
14.5.5. Key Developments
14.5.6. Strategies
14.6. GlaxoSmithKline plc
14.6.1. Company Snapshot
14.6.2. Overview
14.6.3. Financial Overview
14.6.4. Product Portfolio
14.6.5. Key Developments
14.6.6. Strategies
14.7. Johnson & Johnson
14.7.1. Company Snapshot
14.7.2. Overview
14.7.3. Financial Overview
14.7.4. Product Portfolio
14.7.5. Key Developments
14.7.6. Strategies
14.8. MedImmune, LLC
14.8.1. Company Snapshot
14.8.2. Overview
14.8.3. Financial Overview
14.8.4. Product Portfolio
14.8.5. Key Developments
14.8.6. Strategies
14.9. Merck & Co., Inc.
14.9.1. Company Snapshot
14.9.2. Overview
14.9.3. Financial Overview
14.9.4. Product Portfolio
14.9.5. Key Developments
14.9.6. Strategies
14.10. Mitsubishi Tanabe Pharma Corporation
14.10.1. Company Snapshot
14.10.2. Overview
14.10.3. Financial Overview
14.10.4. Product Portfolio
14.10.5. Key Developments
14.10.6. Strategies
14.11. Others
14.11.1. Company Snapshot
14.11.2. Overview
14.11.3. Financial Overview
14.11.4. Product Portfolio
14.11.5. Key Developments
14.11.6. Strategies

CHAPTER 15. RESEARCH APPROACH
15.1. Research Methodology
15.1.1. Initial Data Search
15.1.2. Secondary Research
15.1.3. Primary Research
15.2. Assumptions and Scope

Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157

The report is readily available and can be dispatched immediately after payment confirmation.

To Purchase this Premium Report@ https://www.acumenresearchandconsulting.com/buy-now/0/1599

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.